ERBB2 and neoplasm: In fact, macrophages, alveolar epithelial cells, and fibroblastic reticular cells have been shown to act as drivers of both preexisting and acquired resistance to anti-HER2 agents, and thus, microenvironment and tumor heterogeneity should be considered when designing new treatments [212].